THOUSAND OAKS, Calif. and COLLEGEVILLE, Pa.--(BUSINESS WIRE)--Amgen (NASDAQ: AMGN) and Pfizer Inc. (NYSE: PFE) today announced results from a new trial that demonstrated Enbrel® (etanercept) significantly improved scalp involvement in adult patients with moderate to severe plaque psoriasis, compared with placebo. The data will be presented today at the 69th Annual American Academy of Dermatology (AAD) meeting in New Orleans, La. “At least half of people with plaque psoriasis have involvement on

NEW YORK--(BUSINESS WIRE)--Pfizer Japan Inc. (“Pfizer,” headquarters: Shibuya-ku, Tokyo) and Takeda Pharmaceutical Company Limited (“Takeda,” headquarters: Chuo-ku, Tokyo) announced today an agreement to extend the period for co-promotion in Japan for the rheumatoid arthritis (RA) drug Enbrel® (generic name: etanercept). The companies also signed a new co-promotion agreement in Japan for the investigational drug tofacitinib (development code: CP-690,550), formerly known as tasocitinib, which is

NEW YORK--(BUSINESS WIRE)--Pfizer Inc., together with its collaborator on the Alzheimer’s Immunotherapy Program, Janssen Alzheimer Immunotherapy, is pleased to announce the addition of the National Family Caregivers Association (NFCA), an organization that empowers family caregivers to act on behalf of themselves and their loved ones, as a supporter of The 7 Summits Climb for Alzheimer’s: Memories are Everything campaign. NFCA joins the campaign just as alpine mountaineer and Alzheimer’s disease

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that its board of directors authorized a new share repurchase program of up to $5 billion of its common stock. This is in addition to approximately $4 billion of authorization remaining under its current repurchase program and increases the company’s total repurchase authorization to $9 billion. Pfizer currently expects to repurchase approximately $5 billion of its common stock during 2011 with the remaining authorized amount ava

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE):                   ($ in millions, except per share amounts)             Fourth-Quarter Full-Year 2010   2009   Change 2010   2009 Change Reported Revenues $ 17,561 $ 16,537 6 % $ 67,809 $ 50,009 36 % Reported Net Income(2) 2,890 767 277 % 8,257 8,635 (4 %) Reported Diluted EPS(2) 0.36 0.10 260 % 1.02 1.23 (17 %) Adjusted Income(1) 3,770 3,825 (1 %) 17,983 14,202 27 % Adjusted Diluted EPS(1) 0.47 0.49 (4 %) 2.23 2.02 10 %                        

COLLEGEVILLE, Pa.--(BUSINESS WIRE)--Pfizer Inc. today announced that Dr. Yvonne Greenstreet has been appointed Senior Vice President and Head of Medicines Development for the Specialty Care Business Unit, effective February 1 2011. Upon her arrival, she will assume global responsibility for leading the advancement of the development portfolio, ensuring its alignment with Specialty Care’s strategic objectives. “Yvonne has a strong track record of leadership and outstanding results during her care

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that its wholly-owned subsidiary, Parker Tennessee Corp., has accepted for purchase all of the shares validly tendered and not validly withdrawn pursuant to its tender offer for all outstanding shares of common stock of King Pharmaceuticals, Inc. (NYSE: KG) at a purchase price of $14.25 per share, net to the seller in cash, without interest thereon and subject to any required withholding taxes. The offering period and withdrawal

NEW YORK--(BUSINESS WIRE)--The Healthcare Businesswomen’s Association (HBA) announced that its 2011 “Woman of the Year” is Freda Lewis-Hall, MD, chief medical officer of Pfizer. In her distinguished 30-year career, Dr. Lewis-Hall has held leadership roles in direct patient care, academics, media, government, pharmaceuticals and biotechnology. “I am deeply honored to be named Woman of the Year by the Healthcare Businesswomen’s Association,” said Dr. Lewis-Hall. “HBA has been an agent of positive

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) has been terminated in connection with the tender offer by its wholly-owned subsidiary, Parker Tennessee Corp., to purchase all outstanding shares of common stock of King Pharmaceuticals, Inc. (NYSE: KG) for $14.25 per share, net to the seller in cash, without interest thereon and subject to any required withholding taxes. Termination

NEW YORK & TARRYTOWN, N.Y.--(BUSINESS WIRE)--Pfizer Inc and Progenics Pharmaceuticals, Inc. have learned of a United States market recall of alcohol prep pads and swabs manufactured by the Triad Group. In the interest of patient safety, Pfizer and Progenics are alerting U.S. patients and physicians to Triad’s recall. Triad® Alcohol Prep Pads are packaged for use with the kit presentation of RELISTOR® (methylnaltrexone bromide) Subcutaneous Injection in the U.S. The RELISTOR vial and other compon